Dhib-Jalbut S - Search Results

1

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Voskuhl RR, et al. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29. Lancet Neurol. 2016. PMID: 26621682 Clinical Trial.

2

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.

Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, Weinstock-Guttman B. Freedman MS, et al. Curr Med Res Opin. 2009 Oct;25(10):2459-70. doi: 10.1185/03007990903158364. Curr Med Res Opin. 2009. PMID: 19678753 Review.

3

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.

Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T, Yong VW. Dhib-Jalbut S, et al. J Neuroimmunol. 2006 Jul;176(1-2):198-215. doi: 10.1016/j.jneuroim.2006.03.027. J Neuroimmunol. 2006. PMID: 16983747

4

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

Calabresi PA, Fields NS, Maloni HW, Hanham A, Carlino J, Moore J, Levin MC, Dhib-Jalbut S, Tranquill LR, Austin H, McFarland HF, Racke MK. Calabresi PA, et al. Neurology. 1998 Jul;51(1):289-92. doi: 10.1212/wnl.51.1.289. Neurology. 1998. PMID: 9674825 Clinical Trial.

5

Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.

Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Valenzuela RM, et al. Mult Scler. 2007 Jul;13(6):754-62. doi: 10.1177/1352458506074510. Epub 2007 Mar 15. Mult Scler. 2007. PMID: 17613604 Clinical Trial.

6

Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.

Boppana S, Mindur JE, Balashov KE, Dhib-Jalbut S, Ito K. Boppana S, et al. J Neuroimmunol. 2013 Dec 15;265(1-2):68-74. doi: 10.1016/j.jneuroim.2013.10.007. Epub 2013 Oct 24. J Neuroimmunol. 2013. PMID: 24200257

7

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.

Dhib-Jalbut S. Dhib-Jalbut S. Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9. doi: 10.1212/wnl.58.8_suppl_4.s3. Neurology. 2002. PMID: 11971121 Review.

8

IL-27: a potential biomarker for responders to glatiramer acetate therapy.

Mindur JE, Valenzuela RM, Yadav SK, Boppana S, Dhib-Jalbut S, Ito K. Mindur JE, et al. J Neuroimmunol. 2017 Mar 15;304:21-28. doi: 10.1016/j.jneuroim.2016.07.004. Epub 2016 Jul 17. J Neuroimmunol. 2017. PMID: 27449853

9

Are Periventricular Lesions Specific for Multiple Sclerosis?

Casini G, Yurashevich M, Vanga R, Dash S, Dhib-Jalbut S, Gerhardstein B, Inglese M, Toe W, Balashov KE. Casini G, et al. J Neurol Neurophysiol. 2013 May 3;4(2):150. doi: 10.4172/2155-9562.1000150. J Neurol Neurophysiol. 2013. PMID: 25568815 Free PMC article.

10

Interferon-beta mechanisms of action in multiple sclerosis.

Dhib-Jalbut S, Marks S. Dhib-Jalbut S, et al. Neurology. 2010 Jan 5;74 Suppl 1:S17-24. doi: 10.1212/WNL.0b013e3181c97d99. Neurology. 2010. PMID: 20038758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page